Incidence of bacterial respiratory infection and pneumonia in people with HIV with and without airflow limitation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,9 MB, PDF-dokument

Objectives
We aimed to determine the incidence rate, pathogen composition, and risk factors, particularly airflow limitation, associated with bacterial respiratory infection and pneumonia in a prospective cohort of well-treated people with HIV (PWH) between 2015-2021.

Methods
We included 1007 PWH from the Copenhagen Comorbidity in HIV infection (COCOMO) study. Spirometry was performed at inclusion. Microbiology samples were collected prospectively. Cumulative incidence was determined by the Aalen-Johansen estimator. Cox proportional hazard models were used to calculate risk factors, adjusted for traditional and HIV-specific variables.

Results
The incidence rates of first bacterial respiratory infection and pneumonia were 12.4 (95% CI 9.7-15.5) and 5.5 (95% CI: 3.8-7.7) per 1000 person-years, respectively. The cumulative incidence of pneumonia was four times higher in PWH with airflow limitation (11.8% vs 3.2%, P <0.001). Risk factors for bacterial respiratory infection were airflow limitation (hazard ratio [HR] 2.9, [95% CI: 1.7-5.1], P <0.001), smoking (HR 2.3, [95% CI: 1.4-3.8], P <0.001), and previous AIDS-defining event (HR 2.0, [95% CI: 1.2-3.3], P = 0.009). For pneumonia, airflow limitation (HR 2.7, [95% CI: 1.2-6.3], P = 0.016), smoking (HR 2.5, [95% CI: 1.2-5.4], P = 0.016), and older age (HR 1.5, [95% CI: 1.1-2.1], P = 0.015) were identified as risk factors.

Conclusions
Increased emphasis on airflow limitation prevention, including smoking cessation, may reduce the burden of bacterial respiratory infection and pneumonia in PWH.
OriginalsprogEngelsk
TidsskriftInternational Journal of Infectious Diseases
Vol/bind139
Sider (fra-til)183-191
Antal sider9
ISSN1201-9712
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
This work was supported by the Novo Nordisk Foundation NNF 12495 , Gilead, Rigshospitalet Research Council, Lundbeck Foundation, and Augustinus Foundation .

Funding Information:
This work was supported by the Novo Nordisk Foundation NNF 12495, Gilead, Rigshospitalet Research Council, Lundbeck Foundation, and Augustinus Foundation. The Copenhagen Comorbidity in HIV infection study (NCT02382822) has been approved by the Committee on Health Research Ethics of the Capital Region of Denmark (H-8-2014-004) and the Danish Data Protection Agency. Written informed consent was obtained from all participants. SLH was responsible for concept, data collection, statistical analysis and drafted the manuscript. AWS was responsible for data collection. MHS was responsible for concept, supervised the statistical analyses and interpretation of data, and edited the manuscript. DLM supervised the statistical analyses and edited the manuscript. CSJ was responsible for microbiology and edited the manuscript. NSA, RFT, TB, and JSJ were responsible for concept and editing of the manuscript. SDN was responsible for concept, data collection and has had content review and editing input. We sincerely thank all the participants of the Copenhagen Comorbidity in HIV infection study for their dedicated participation. We thank the staff at the Department of Infectious Diseases at Rigshospitalet, for their participation.

Publisher Copyright:
© 2023

ID: 380292556